pharmacokinetic models of transdermal drug delivery … · pharmacokinetic models of transdermal...
TRANSCRIPT
![Page 1: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/1.jpg)
Pharmacokinetic models of transdermal drug delivery
Annette L. Bunge
Opportunities and pitfalls
![Page 2: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/2.jpg)
PK models of transdermal drug delivery
http://en.wikipedia.org/wiki/Transdermal_patchTime
Pla
sma
conc
entra
tion
![Page 3: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/3.jpg)
Combine three models
skin
transdermaldevice
blood
Model 1Release from device
Model 2Skin permeation
Model 3Systemic distribution/metabolism/elimination
![Page 4: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/4.jpg)
Transdermal device model
Represent the device design including all diffusion barriersPartitioning between all parts of deviceDissolution of undissolved drug(if present)
skin
blood
transdermaldevice
![Page 5: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/5.jpg)
transdermaldevice
Systemic pharmacokinetic model
Could be a 1 or multi-compartment modelCould be a physically-based PK (PBPK) modelModel parameters generally derived by separate experiment (e.g., plasma C arising from IV delivery)
skin
blood
![Page 6: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/6.jpg)
SC alone or with other layer(s)
Skin model
stratum corneum
viable epidermis
dermis
transdermaldevice
blood
skin
![Page 7: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/7.jpg)
Skin model
Simple or complex description of each layer
“Stirred” compartment
Average C(t)
transdermaldevice
blood
skin
![Page 8: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/8.jpg)
Average C(t)
Skin model
Simple or complex description of each layer
“Stirred” compartmentDiffusion barrier
Dlayer
C(t,x)
transdermaldevice
blood
skin
![Page 9: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/9.jpg)
Dlayer
C(t,x)
Skin model
Simple or complex description of each layer
“Stirred” compartmentDiffusion barrierDiffusion barrier with multiple, multiphasic pathways
D1, D2, K1/2
C1(t,x,y,z?)C2(t,x,y,z?)
transdermaldevice
blood
skin
![Page 10: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/10.jpg)
PK modelling opportunities
Test hypothesesPhysically-based models precisely specify mechanisms Identify mechanisms by comparing model predictions with experimentsDisagreement with experiment proves that the model is wrongAgreement with experiment does NOT prove that the model is correct (other models might alsoagree)
![Page 11: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/11.jpg)
PK modelling opportunities (even more)
Simulate experimentsPhysicochemical parameters are known preciselyTest sensitivity of proposed data analysis; e.g.
Does the data analysis give the correct physicochemical parameters?Will the proposed bioequivalence test metric give the correct result?
![Page 12: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/12.jpg)
PK modelling opportunities (still more)
Answer what-if questions
![Page 13: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/13.jpg)
PK modelling opportunities (still more)
Answer what-if questions; e.g.What happens if the TDD is changed?
Gupta et al., J Pain Symptom Manage, 7:S17-26 (1992)
![Page 14: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/14.jpg)
Effect of membrane thickness(e.g., manufacturing variation in TDD)
Gupta et al., J Pain Symptom Manage, 7:S17-26 (1992)
![Page 15: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/15.jpg)
PK modelling opportunities (still more)
Answer what-if questions; e.g.What happens if the TDD is changed?What if the SC thickness is different?
Gupta et al., J Pain Symptom Manage, 7:S17-26 (1992)
![Page 16: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/16.jpg)
Effect of SC thickness(e.g., TDD applied to different sites)
Gupta et al., J Pain Symptom Manage, 7:S17-26 (1992)
![Page 17: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/17.jpg)
PK modelling opportunities (still more)
Answer what-if questions; e.g.What happens if the TDD is changed?What if the SC thickness is different?What if the clearance rate changes?
Gupta et al., J Pain Symptom Manage, 7:S17-26 (1992)
![Page 18: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/18.jpg)
Effect of clearance rate
Gupta et al., J Pain Symptom Manage, 7:S17-26 (1992)
![Page 19: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/19.jpg)
Pitfalls
Results are plausible but wrongUnreasonable model parameters are usedNon-unique solutionsMeaningless extrapolations
![Page 20: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/20.jpg)
Pitfalls: Results are plausible but wrong
Just because the calculated results look OK does not mean they are correct
![Page 21: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/21.jpg)
Pitfalls
Errors in one (or more) mathematical elementsMass balance in and between compartmentsThermodynamic limits(partition coefficients at boundaries and equilibrium)Constitutive equations(describing how rates of transport and reaction vary with drug concentration)
: Results are plausible but wrong
![Page 22: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/22.jpg)
Example TDD model
International J of Pharmaceutics, 71:237-243 (1991)
Drug: ClenbuterolEliminated slowly from the body; ½ life is ~ 33 hTDD device: Polymer matrix containing dissolved drug
![Page 23: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/23.jpg)
Example TDD model
Matrix-type TDD
MembraneCm (x,t)
Initial ConcentrationCm,o < Cm,sat
![Page 24: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/24.jpg)
Example TDD model
MatrixMembrane
Cm(x,t)
Stratum Corneum
MembraneCsc(x,t)
Initial ConcentrationCsc = 0
![Page 25: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/25.jpg)
Example TDD model
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
Viable Epidermis/Dermis
StirredCe(t)
Initial ConcentrationCe = 0
![Page 26: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/26.jpg)
Tissue
Stirredmt(t)
Initial Massmt = 0
kel
Example TDD model
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
VE/DermStirred
Ce(t)
Plasma
Stirredmp(t)
Initial Massmp = 0
kpt
ktp
![Page 27: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/27.jpg)
Example TDD model
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
VE/DermStirred
Ce(t)
PlasmaStirredmp(t)
TissueStirred
mt(t)
kpt
ktp
kel
kpe
kep
![Page 28: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/28.jpg)
Example TDD model: Model parameters
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
VE/DermStirred
Ce(t)
PlasmaStirredmp(t)
TissueStirred
mt(t)
kep
kpe
kpt
ktp
kel
Operational Parameters: TDD area, initial concentration
![Page 29: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/29.jpg)
Example TDD model: Model parameters
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
VE/DermStirred
Ce(t)
PlasmaStirredmp(t)
TissueStirred
mt(t)
kep
kpe
kpt
ktp
kel
Dm Dsc
Km/sc Ksc/e
kep
kpe
kel
kpt
ktp
VDLm Lsc Le
Model parameters: 13
Operational Parameters: TDD area, initial concentration
![Page 30: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/30.jpg)
Example TDD model: Model parameters
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
VE/DermStirred
Ce(t)
PlasmaStirredmp(t)
TissueStirred
mt(t)
kep
kpe
kpt
ktp
kel
Dm Dsc
Km/sc Ksc/e
kep
kpe
kel
kpt
ktp
VDLm Lsc Le
Operational Parameters: TDD area, initial concentration
Model parameters: 13Independent experiment: 6Regressed to data: 7
![Page 31: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/31.jpg)
kep
kpe
Operational Parameters: TDD area, initial concentration
Example TDD model: Model parameters
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
VE/DermStirred
Ce(t)
PlasmaStirredmp(t)
TissueStirred
mt(t)
kpt
ktp
kel
Dm Dsc
Km/sc Ksc/e = 1
kep
kpe
kel
kpt
ktp
VDLm Lsc Le
Model parameters: 13Independent experiment: 6Regressed to data: 7
X7X6
- Plasma concentration(t)- Mass in urine(t)- Mass in TDD (? at end)
![Page 32: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/32.jpg)
kep
kpe
Example TDD model: Model equations
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
VE/DermStirred
Ce(t)
PlasmaStirredmp(t)
TissueStirred
mt(t)
kpt
ktp
kel
![Page 33: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/33.jpg)
/ interface
e scm sc pe p ep e
x sc e
dm CA D k m k mdt x =
∂= − + −
∂
kep
kpe
Example TDD model: Model equations
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
VE/DermStirred
Ce(t)
PlasmaStirredmp(t)
TissueStirred
mt(t)
kpt
ktp
kel
Change in mass in VE/D with time
Transfer infrom SC
Transfer infrom plasma
Transfer outto plasma
= + ̶
![Page 34: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/34.jpg)
// interface
e sce sc e sc pe p ep e
x sc e
dm CK L D k m k mdt x =
∂= + −
∂
/ interface
e scm sc pe p ep e
x sc e
dm CA D k m k mdt x =
∂= − + −
∂
kep
kpe
Example TDD model: Model equations
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
PlasmaStirredmp(t)
TissueStirred
mt(t)
kpt
ktp
kel
=In thepaper
VE/DermStirred
Ce(t)
![Page 35: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/35.jpg)
kep
kpe
Example TDD model: Model equations
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
PlasmaStirredmp(t)
TissueStirred
mt(t)
kpt
ktp
kel
m sc
e scm sc pe p ep e
x L L
dm Cf A D k m k mdt x = +
∂= − + −
∂
/where = 1/( ) in unknown unitse sc e mf K L A length=
This makes the equation dimensionally inconsistent.
VE/DermStirred
Ce(t)
![Page 36: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/36.jpg)
Example TDD model: Model calculations
Göpferich and Lee, Intl J Pharmaceut, 71:237-43 (1991)
Model calculationfrom paper
Plasma concentration
![Page 37: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/37.jpg)
Example TDD model: Model calculations
Reported Km/sc = 0.45, f = 0.36
Model calculationfrom paper
Plasma concentration
![Page 38: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/38.jpg)
Example TDD model: Model calculations
Göpferich and Lee, Intl J Pharmaceut, 71:237-43 (1991)
Reported Km/sc = 0.45, f = 0.36Km/sc = 1 (in Fig. 5), f = 0.53
Plasma concentration
![Page 39: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/39.jpg)
Example TDD model: Model calculations
Göpferich and Lee, Intl J Pharmaceut, 71:237-43 (1991)
Reported Km/sc = 0.45, f = 0.36Km/sc = 1 (in Fig. 5), f = 0.53Km/sc = 1/0.45, f = 1
Plasma concentration
![Page 40: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/40.jpg)
Example TDD model: Model calculations
Reported Km/sc = 0.45, f = 0.36Km/sc = 1 (in Fig. 5), f = 0.53Km/sc = 1/0.45, f = 1
No difference
Mass eliminated
![Page 41: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/41.jpg)
Example TDD model: Model calculations
Reported Km/sc = 0.45, f = 0.36Km/sc = 1 (in Fig. 5), f = 0.53Km/sc = 1/0.45, f = 1
Difference might be too small to discriminate between calculations
Mass fraction in TDD
![Page 42: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/42.jpg)
Example TDD model: Model calculations
Reported Km/sc = 0.45, f = 0.36Km/sc = 1 (in Fig. 5), f = 0.53Km/sc = 1/0.45, f = 1
Mass fraction in TDD
All results look reasonable
![Page 43: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/43.jpg)
Example TDD model: Model calculations
Mass balance error = 1 –
(Mass in TDD + Mass in all compartments + Mass eliminated) / (Initial mass in TDD)
Reported Km/sc = 0.45, f = 0.36Km/sc = 1 (in Fig. 5), f = 0.53Km/sc = 1/0.45, f = 1
Mass balance
Large errors inmass balance
when f ≠ 1
![Page 44: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/44.jpg)
Pitfalls
Errors in one (or more) mathematical elementsMass balance in and between compartmentsThermodynamic limits(partition coefficients at boundaries and equilibrium)Constitutive equations(describing how rates of transport and reaction vary with drug concentration)
: Results are plausible but wrong
Errors in mass balance equations are revealed by doing an overall mass balance.
![Page 45: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/45.jpg)
Pitfalls
Errors in one (or more) mathematical elementsMass balance in and between compartmentsThermodynamic limits(partition coefficients at boundaries and equilibrium)Constitutive equations(describing how rates of transport and reaction vary with drug concentration)
: Results are plausible but wrong
Errors in mass balance equations are revealed by doing an overall mass balance.Mass balances should be done and results reported as “proof” of model correctness.
![Page 46: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/46.jpg)
Pitfalls
Errors in one (or more) mathematical elementsMass balance in and between compartmentsThermodynamic limits(partition coefficients at boundaries and equilibrium)Constitutive equations(describing how rates of transport and reaction vary with drug concentration)
: Results are plausible but wrong
Errors in mass balance equations are revealed by doing an overall mass balance.Mass balances should be done and results reported as “proof” of model correctness.
Errors in thermodynamic limits or constitutive equations may not produce mass balance errors (and thus, may not be discovered)
![Page 47: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/47.jpg)
Pitfalls
Errors in one (or more) mathematical elementsMass balance in and between compartmentsThermodynamic limits(partition coefficients at boundaries and equilibrium)Constitutive equations(describing how rates of transport and reaction vary with drug concentration)
Numerical errors
: Results are plausible but wrong
![Page 48: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/48.jpg)
Example TDD model: Numerical Errors
Numerical solutions approximate derivatives in the model equationsDerivative approximations may be poor:
If spacing between positions (nodes) at which concentration is calculated are spaced too far apart (in finite-difference methods)If size of volume within which concentration is calculated are too large (in finite-element methods)
Numerical errors may be discovered by errors in the mass balance.
![Page 49: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/49.jpg)
Example TDD model: Numerical Errors
Model ParametersCm,o = 91.9 mg/mLLsc = 15 μmLe = 50 μmLm = 13.6 μmKsc/m = 1000Ksc/e = 25Ke/p = 1kep = 15 h-1
kpe = 1.33 x 10-4 h-1
kpt = 0.2 h-1
ktp = 0.5 h-1
kel = 2.8 h-1
VD = 1130 mLDm = 2 x 10-8 cm2/hDsc = 1 x 10-8 cm2/h
No of nodes in matrix = 6
11
>21
At 8 h
![Page 50: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/50.jpg)
Example TDD model: Numerical Errors
# nodes in SC = 21
11
21
# nodes in TDD = 6# nodes in TDD = 6
# nodes in SC = 6
11, 21
Optimize # of nodes in all compartments
![Page 51: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/51.jpg)
Example TDD model: Numerical Errors
# nodes in SC = 21
11
21
# nodes in TDD = 6# nodes in TDD = 6
# nodes in SC = 6
11, 21
Numerical errors are generally larger at shorter times
![Page 52: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/52.jpg)
Example TDD model: Numerical Errors
# nodes in SC = 21
11
21
# nodes in TDD = 6# nodes in TDD = 6
# nodes in SC = 6
11, 21
Numerical errors are generally larger at shorter timesErrors at shorter times can affect longer time results
![Page 53: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/53.jpg)
Pitfalls:
Results are only as good as the model parameters used in the calculations
: Unreasonable parameter values
From http://www.donwardell.ca/cartoons.php
![Page 54: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/54.jpg)
Pitfalls
Poorly chosen values
: Unreasonable parameter values
![Page 55: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/55.jpg)
kep
kpe
Example TDD model: Model Parameter
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
VE/DermStirred
Ce(t)
PlasmaStirredmp(t)
TissueStirred
mt(t)
kpt
ktp
kelKsc/e = 1
![Page 56: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/56.jpg)
kep
kpe
Example TDD model: Model Parameter
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
VE/DermStirred
Ce(t)
PlasmaStirredmp(t)
TissueStirred
mt(t)
kpt
ktp
kelKsc/e = 1
Estimated Koct/w = 100Ksc/e = 1 does NOT seem reasonable
logKsc/e ≈ 0.7 logKoct/w
Ksc/e ≈ 25
![Page 57: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/57.jpg)
Pitfalls
Poorly chosen valuesParameter regression without consideration of connections or limits in the parameter values
: Unreasonable parameter values
![Page 58: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/58.jpg)
kep
kpe
Example TDD model: Parameter limits
MatrixMembrane
Cm(x,t)
SCMembrane
Csc(x,t)
VE/DermStirred
Ce(t)
PlasmaStirredmp(t)
TissueStirred
mt(t)
kpt
ktp
kel
kep = 1.47 h-1 and kpe = 12.6 h-1
Göpferich and Lee, Intl J Pharmaceut, 71:237-43 (1991)
Mass transfer rate from VE to plasma = kep me ̶ kpe mp
![Page 59: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/59.jpg)
Example TDD model: Parameter limits
Mass transfer rate from VE to plasma = kep me ̶ kpe mp
Values for kep and kpe are related by equilibrium limits.
At equilibrium between VE and plasma: Ce = Ke/p Cp
Mass transfer rate from VE to plasma = 0
/e p e mpe ep
D
K L Ak k
V⎛ ⎞
= ⎜ ⎟⎝ ⎠
kep and kpe are NOT independent!
![Page 60: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/60.jpg)
Example TDD model: Parameter limits
From Göpferich and Lee, 1991:kep = 1.47 h-1 and kpe = 12.6 h-1
Le = 50 μm, VD = 113 L and Am = 2 cm2
If Ke/p ≈ 1 for kep = 1.47 h-1
kpe = 13 x 10-8 h-1 (NOT 12.6 h-1)
![Page 61: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/61.jpg)
Pitfalls
Poorly chosen valuesParameter regression without consideration of connections or limits in the parameter valuesPoorly chosen or incorrect model parameters for a model compartment:
May not matter if that compartment is not rate controlling, butCould matter if conditions change (e.g., longer times, other parameter values change)Might lead to misinterpretation of the physical situation
: Unreasonable parameter values
![Page 62: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/62.jpg)
Pitfalls
Even simple PK models of TDD have many model parametersCommonly multiple combinations of parameter values provide similar resultsDiscriminating between model parameter choices is especially difficult if experimental data are variable
: Non-unique solutions
![Page 63: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/63.jpg)
Pitfalls
0 2 4 6 8Time (days)
0
40
80
120
: Non-unique solutions
Plasma concentration Mass fraction eliminated
Gopferich & Lee, 1991
![Page 64: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/64.jpg)
Pitfalls
0 2 4 6 8Time (days)
0
40
80
120
: Non-unique solutions
Plasma concentration Mass fraction in TDD
![Page 65: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/65.jpg)
Pitfalls
Multiple sets of model parameters may fit the data but extrapolate to different resultsExtrapolation with model parameters determined by regression to data are particularly unreliableExtrapolations may be done with more confidence if the model parameters have been determined in separate experiments (and fit the experimental data)
: Meaningless extrapolations
![Page 66: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/66.jpg)
0 14 28 42 56Time (days)
0
40
80
120
160
Pitfalls
Plasma concentration
Gopferich & Lee, 1991
: Meaningless extrapolations
Mass fraction eliminated
![Page 67: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/67.jpg)
0 14 28 42 56Time (days)
0
40
80
120
160
Pitfalls
Plasma concentration
Gopferich & Lee, 1991
: Meaningless extrapolations
Mass fraction in TDD
![Page 68: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/68.jpg)
Recommendations for PK models of TDD
Write out all equationsWord descriptions leave room for interpretation
Describe derivation of all model parametersRecognize physical constraints on model parameter values
Not all can be set independentlyIndependent experimental sources for model parameters are preferred over regressionCheck the mass balance and report resultsExtrapolate cautiously
![Page 69: Pharmacokinetic models of transdermal drug delivery … · Pharmacokinetic models of transdermal drug delivery Annette L. Bunge Opportunities and pitfalls](https://reader033.vdocument.in/reader033/viewer/2022051010/5ad2d3b97f8b9a0f198cd443/html5/thumbnails/69.jpg)
The End
Questions?